A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (NCT07522073)
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Who can join: Review the eligibility criteria below.
Location: Investigative Site US058 — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (219 Sites)
Showing the first 25 of 219 sites.
- Investigative Site US058 — Birmingham, Alabama
- Investigative Site US016 — Anchorage, Alaska
- Investigative Site US026 — Chandler, Arizona
- Investigative Site US045 — Tucson, Arizona
- Investigative Site US051 — Duarte, California
- Investigative Site US085 — Fullerton, California
- Investigative Site US054 — La Jolla, California
- Investigative Site US086 — Long Beach, California
- Investigative Site US027 — Los Angeles, California
- Investigative Site US036 — Los Angeles, California
- Investigative Site US048 — Los Angeles, California
- Investigative Site US049 — Orange, California
- Investigative Site US034 — San Francisco, California
- Investigative Site US001 — Santa Monica, California
- Investigative Site US071 — Denver, Colorado
- Investigative Site US013 — Washington D.C., District of Columbia
- Investigative Site US046 — Washington D.C., District of Columbia
- Investigative Site US072 — Fort Myers, Florida
- Investigative Site US083 — Jacksonville, Florida
- Investigative Site US075 — Miami, Florida
- Investigative Site US074 — St. Petersburg, Florida
- Investigative Site US073 — West Palm Beach, Florida
- Investigative Site US023 — Atlanta, Georgia
- Investigative Site US079 — Chicago, Illinois
- Investigative Site US030 — Evanston, Illinois
📞 Contact the Study Coordinator
Phone: (855) 463-3463
Email: medinfo@incyte.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumors
- Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
- Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
- A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
- Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona
Explore by condition: All Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.